Please login to the form below

Not currently logged in
Email:
Password:

J&J’s clinical research neuroscience director joins MedAvante

Dr Michael Ropacki becomes head of R&D at the clinical data service

MedAvante Dr Michael RopackiGlobal clinical data services company MedAvante has appointed Dr Michael Ropacki as vice president of research and development.

Dr Ropacki joins MedAvante from Johnson & Johnson, where he served as clinical research neuroscience director in its Janssen research and development arm.

Prior to this, he was medical director, global medical affairs for Janssen's Alzheimer's disease immunotherapy unit from June 2011 to May 2013.

He also brings experience as associate director and principal clinical scientist at Johnson & Johnson's biotech Centocor, which he first joined as a clinical scientist in 2004.

Paul Gilbert, MedAvante's chief executive officer, said: “Michael Ropacki is widely recognised for the groundbreaking trial methodology he has implemented for registries and prospective cohort studies.

“He also brings extensive experience in psychiatry, neurology and dermatology, making him an ideal addition to MedAvante's scientific leadership team.”

24th February 2017

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Attigo (part of the Mednet Group)

Inclusion drives innovation. Attigo, a social enterprise, helps pharma and the socially conscious business shape the future by engaging with...

Latest intelligence

Peter Howarth
Exploring the potential of eosinophils
GSK’s Peter Howarth talks about the emerging research that suggests there is a varied role for eosinophils...
white house
Eliminating pharmaceutical rebates, is this déjà vu?
By Andrew Parece and Matthew Majewski...
Patients are ready to embrace decentralised clinical trials, are you?
Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...

Infographics